Overall Survival Data with PARP Inhibitor: Myth vs. Reality - Webinar-Webinar Recording - Overall Survival Data with PARP Inhibitor: Myth vs. Reality

Webinar Recording - Overall Survival Data with PARP Inhibitor: Myth vs. Reality

Video Transcription

Video Summary

In this video, Mansoor Samirzah, Chief Oncologist at the Department of Oncology at Rijkshospitalet in Copenhagen, Denmark, and Medical Director of Nordic Society of Gynecologic Oncology, discusses the topic of overall survival with PARP inhibitors in gynecologic oncology. Samirzah provides an overview of the studies conducted on PARP inhibitors in platinum-sensitive relapse settings, highlighting the significance of these inhibitors in changing the management of patients with high-grade serious ovarian cancer. He emphasizes that studies have shown a significant benefit in progression-free survival (PFS) with PARP inhibitors, and discusses the potential reasons for the lack of significant benefits in overall survival (OS) in these studies. Samirzah also presents the results of the NORA trial, which demonstrate a positive trend in overall survival with the use of the PARP inhibitor norepinephrine. He concludes by stating that PARP inhibitors should be considered for maintenance therapy in patients responding to subsequent platinum-based therapy, and highlights the need for further research to better understand the impact of PARP inhibitors on overall survival. The video was presented as part of the Advances and Update webinar, organized by the Educational Committee of the International Gynecologic Cancer Society (IGCS).

Keywords

PARP inhibitors

gynecologic oncology

overall survival

platinum-sensitive relapse

progression-free survival

maintenance therapy

NORA trial